The PE Ratio as of July 2024 (TTM) for Janux Therapeutics, Inc. (JANX) is -36.66

According to Janux Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -36.66. This represents a change of 148.50% compared to the average of -14.75 of the last 4 quarters.

Janux Therapeutics, Inc. (JANX) Historical PE Ratio (quarterly & annually)

How has JANX PE Ratio performed in the past?

The mean historical PE Ratio of Janux Therapeutics, Inc. over the last ten years is -97.87. The current -36.66 PE Ratio has changed 3.65% with respect to the historical average. Over the past ten years (40 quarters), JANX's PE Ratio was at its highest in in the June 2023 quarter at -7.09. The PE Ratio was at its lowest in in the March 2021 quarter at -109.84.

Janux Therapeutics, Inc. (JANX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Janux Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Janux Therapeutics, Inc. (JANX) Average PE Ratio

How has JANX PE Ratio performed in the past?

The current PE Ratio of Janux Therapeutics, Inc. (JANX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Janux Therapeutics, Inc. (JANX) PE Ratio vs. Peers

How is JANX’s PE Ratio compared to its peers?

Janux Therapeutics, Inc.’s PE Ratio is less than Mineralys Therapeutics, Inc. (-6.65), less than Eliem Therapeutics, Inc. (-16.46), less than Anebulo Pharmaceuticals, Inc. (-6.10), less than Rezolute, Inc. (-4.09), less than Keros Therapeutics, Inc. (-9.61), less than Fennec Pharmaceuticals Inc. (63.56), less than Edgewise Therapeutics, Inc. (-15.70), less than Harmony Biosciences Holdings, Inc. (13.98), less than Molecular Partners AG (-3.15), less than MediciNova, Inc. (-7.64), less than Champions Oncology, Inc. (-9.15), less than Cyteir Therapeutics, Inc. (-3.52), less than Aerovate Therapeutics, Inc. (-0.68), less than Adagene Inc. (-2.55), less than Acrivon Therapeutics, Inc. Common Stock (-3.12), less than AN2 Therapeutics, Inc. (-1.21),

Build a custom stock screener for Janux Therapeutics, Inc. (JANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Janux Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Janux Therapeutics, Inc. (JANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Janux Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.